Key result
SIRPα expression rose 3.6-fold in CKD mouse hearts, and global or cardiac-specific SIRPα knockout preserved left ventricular systolic function and prevented ~3-fold increases in myocardial fibrosis.
Why the study?
CKD causes increased myocardial mass despite near-normal blood pressure, suggesting an alternative trigger, and SIRPα was evaluated as a potential driver of CKD-induced adverse cardiac remodeling.
Does genetic suppression of SIRPα preserve myocardial insulin/IGF1R signaling and prevent adverse cardiac remodeling and dysfunction in mouse models of chronic kidney disease?
Does genetic suppression of SIRPα preserve myocardial insulin/IGF1R signaling and prevent adverse cardiac remodeling and dysfunction in mouse models of chronic kidney disease?
Identifies circulating and myocardial SIRPα as a myokine that directly binds and impairs cardiac IGF1R signaling to drive CKD-induced cardiomyopathy and fibrosis, representing a novel therapeutic target for uremic heart failure.
Answers are grounded in this paper and cite their sources.
SIRPα targeting remains investigational in uremic cardiomyopathy; leaves open translation from mouse models to human CKD-related heart failure.
BACKGROUND: Chronic kidney disease (CKD) is characterized by increased myocardial mass despite near-normal blood pressure, suggesting the presence of a separate trigger. A potential driver is SIRPα (signal regulatory protein alpha)-a mediator impairing insulin signaling. The objective of this study is to assess the role of circulating SIRPα in CKD-induced adverse cardiac remodeling. METHODS: SIRPα expression was evaluated in mouse models and patients with CKD. Specifically, mutant, muscle-specific, or cardiac muscle-specific SIRPα KO (knockout) mice were examined after subtotal nephrectomy. Cardiac function was assessed by echocardiography. Metabolic responses were confirmed in cultured muscle cells or cardiomyocytes. RESULTS: We demonstrate that SIRPα regulates myocardial insulin/IGF1R (insulin growth factor-1 receptor) signaling in CKD. First, in the serum of both mice and patients, SIRPα was robustly secreted in response to CKD. Second, cardiac muscle upregulation of SIRPα was associated with impaired insulin/IGF1R signaling, myocardial dysfunction, and fibrosis. However, both global and cardiac muscle-specific SIRPα KO mice displayed improved cardiac function when compared with control mice with CKD. Third, both muscle-specific or cardiac muscle-specific SIRPα KO mice did not significantly activate fetal genes and maintained insulin/IGF1R signaling with suppressed fibrosis despite the presence of CKD. Importantly, SIRPα directly interacted with IGF1R. Next, rSIRPα (recombinant SIRPα) protein was introduced into muscle-specific SIRPα KO mice reestablishing the insulin/IGF1R signaling activity. Additionally, overexpression of SIRPα in myoblasts and cardiomyocytes impaired pAKT (phosphorylation of AKT) and insulin/IGF1R signaling. Furthermore, myotubes and cardiomyocytes, but not adipocytes treated with high glucose or cardiomyocytes treated with uremic toxins, stimulated secretion of SIRPα in culture media, suggesting these cells are the origin of circulating SIRPα in CKD. Both intracellular and extracellular SIRPα exert biologically synergistic effects impairing intracellular myocardial insulin/IGF1R signaling. CONCLUSIONS: Myokine SIRPα expression impairs insulin/IGF1R functions in cardiac muscle, affecting cardiometabolic signaling pathways. Circulating SIRPα constitutes an important readout of insulin resistance in CKD-induced cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Thomas et al. (2022) studied Chronic kidney disease (CKD)-induced cardiomyopathy. SIRPα genetic knockout (global, muscle-specific, or cardiac-specific) and exogenous recombinant SIRPα exposure vs. Wild-type or littermate flox control mice with subtotal nephrectomy (CKD) or sham operation was evaluated on Myocardial insulin/IGF1R signaling, left ventricular systolic function (EF%, FS%, CO), and myocardial fibrosis (p=<0.05). SIRPα expression rose 3.6-fold in CKD mouse hearts, and global or cardiac-specific SIRPα knockout preserved left ventricular systolic function and prevented ~3-fold increases in myocardial fibrosis.
Synapse has enriched 10 related papers. Consider them for comparative context: